Analysis of 1-year Vertebral Fracture Risk Reduction Data in Treatments for Osteoporosis

Southern Medical Journal

Volumn 96, Issue 5, 2003, Pages 478-485

  Miller, Paul ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b University of Colorado Health Sciences Center   (United States)

Author keywords

Bisphosphonates; Glucocorticoid induced osteoporosis; Osteoporosis; Postmenopausal osteoporosis; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; ESTROGEN; GLUCOCORTICOID; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN;

BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; FEMALE; FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; META ANALYSIS; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; SPINE RADIOGRAPHY; TREATMENT OUTCOME; VERTEBRA FRACTURE; ADULT; MALE; RISK REDUCTION; SPINE FRACTURE; TIME;

ADULT; CLINICAL TRIALS; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RISK REDUCTION BEHAVIOR; SPINAL FRACTURES; TIME FACTORS;

EID: 0041465875     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000067661.21765.FC     Document Type: Review

References (62)

1. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-650.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
3. Wasnich RD. Vertebral fracture epidemiology. Bone 1996;18(3 Suppl):179S-183S.
4. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001;7:293-312.
5. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-1801.
6. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001;44:1496-1503.
7. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990;112:352-364.
8. Ross PD. Clinical consequences of vertebral fractures. Am J Med 1997;103:30S-43S.
9. Vogt TM, Ross PD, Palermo L, Musliner T, Genant HK, Black D, et al. Vertebral fracture prevalence among women screened for the Fracture Intervention Trial and a simple clinical tool to screen for undiagnosed vertebral fractures: Fracture Intervention Trial Research Group. Mayo Clin Proc 2000;75:888-896.
10. O'Neill TW, Silman AJ. Definition and diagnosis of vertebral fracture. J Rheumatol 1997;24:1208-1211.
11. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-2318.
12. Gold DT. The nonskeletal consequences of osteoporotic fractures: Psychologic and social outcomes. Rheum Dis Clin North Am 2001;27:255-262.
13. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Intern Med 1998;128:793-800.
14. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures: Fracture Intervention Trial Research Group. Arch Intern Med 2000;160:77-85.
15. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323.
16. Genant HK, Li J, Wu CY, Shepherd JA. Vertebral fractures in osteoporosis: A new method for clinical assessment. J Clin Densitom 2000;3:281-290.
17. Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA. Instant vertebral assessment: A noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 2001;4:373-380.
18. Melton LJ III, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999;10:214-221.
19. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-739.
20. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-923.
21. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures: Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:821-828.
22. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: A prospective study-Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999;159:1215-1220.
23. Walker-Bone K, Dennison E, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2001;27:1-18.
24. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-561.
25. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-720.
26. Siwek J, Gourlay ML, Slawson DC, Shaughnessy AF. How to write an evidence-based clinical review article. Am Fam Physician 2002;65:251-258.
27. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis: Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
28. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial-Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352.
29. Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ, et al. Number and type of vertebral deformities: Epidemiological characteristics and relation to back pain and height loss-European Vertebral Osteoporosis Study Group. Osteoporos Int 1999;9:206-213.
30. Genant HK. Assessment of vertebral fractures in osteoporosis research. J Rheumatol 1997;24:1212-1214.
31. Genant HK, Engelke K, Fuerst T, Gluer CC, Grampp S, Harris ST, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996;11:707-730.
32. Kiel D. Assessing vertebral fractures: National Osteoporosis Foundation Working Group on Vertebral Fractures. J Bone Miner Res 1995;10:518-523.
33. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women: Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16.
34. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
35. Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001;110:442-450.
36. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 2001;285:2891-2897.
37. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 2002;137:526-528.
38. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
39. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
40. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study-PROOF Study Group. Am J Med 2000;109:267-276.
41. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial-Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
42. Procter & Gamble Pharmaceuticals. Actonel full prescribing information. Cincinnati, OH, Procter & Gamble Pharmaceuticals, 2002.
43. Watts NB, Adami S, Chesnut C. Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 2001;16(Suppl 1):S407 (abstract).
44. Chesnut C, Li Z, Meredith M, et al. Vertebral fracture risk reduction with risedronate in osteoporotic women: A meta-analysis of individual patient data across 5 studies. Presented at the Endocrine Society 84th Annual Meeting, June 19-22, 2002, San Francisco, CA (abstract P3-359).
45. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001;344:333-340.
46. Cohen S, Roux C, Eastell R, et al. Risedronate rapidly and consistently reduces risk of vertebral fracture in patients with varying degree of osteoporotic severity. Arthritis Rheum 2000;43(Suppl):S197 (abstract).
47. Merck & Co., Inc. Fosamax full prescribing information. West Point, PA, Merck & Co., Inc., 2000.
48. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443.
49. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial-FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-4124.
50. Levis S, Quandt SA, Thompson D, Scott J, Schneider DL, Ross PD, et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002;50:409-415.
51. Quandt SA. Alendronate reduces the risk of clinical vertebral fracture in osteopenic women: Data from FIT. J Bone Min Res 2000;15(Suppl 1):S551 (abstract M400).
52. Eli Lilly and Co. Evista full prescribing information. Indianapolis, IN, Eli Lilly and Co., 2001.
53. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
54. Pols H, Eastell R, Delmas P, et al. Early onset and sustained efficacy of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4-year results from the MORE trial. Bone 2001;28(Suppl):S85 (abstract OR64).
55. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37:1499-1505.
56. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial-European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000;15:1006-1013.
57. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-285.
58. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-299.
59. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom 1998;1:395-402.
60. Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass: Fracture Intervention Trial Research Group. J Am Geriatr Soc 2000;48:241-249.
61. Felson DT. Bias in meta-analytic research. J Clin Epidemiol 1992;45:885-892.
62. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-1069.